|
Gene: SLC43A2 |
Gene summary for SLC43A2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC43A2 | Gene ID | 124935 |
Gene name | solute carrier family 43 member 2 | |
Gene Alias | LAT4 | |
Cytomap | 17p13.3 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q8N370 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
124935 | SLC43A2 | P2T-E | Human | Esophagus | ESCC | 7.68e-09 | 2.78e-01 | 0.1177 |
124935 | SLC43A2 | P4T-E | Human | Esophagus | ESCC | 5.15e-04 | 1.73e-01 | 0.1323 |
124935 | SLC43A2 | P8T-E | Human | Esophagus | ESCC | 7.89e-11 | 1.32e-01 | 0.0889 |
124935 | SLC43A2 | P9T-E | Human | Esophagus | ESCC | 1.34e-02 | 6.55e-02 | 0.1131 |
124935 | SLC43A2 | P12T-E | Human | Esophagus | ESCC | 9.86e-07 | 1.41e-01 | 0.1122 |
124935 | SLC43A2 | P15T-E | Human | Esophagus | ESCC | 3.39e-03 | 1.99e-01 | 0.1149 |
124935 | SLC43A2 | P16T-E | Human | Esophagus | ESCC | 7.85e-31 | 6.29e-01 | 0.1153 |
124935 | SLC43A2 | P21T-E | Human | Esophagus | ESCC | 4.41e-19 | 3.56e-01 | 0.1617 |
124935 | SLC43A2 | P22T-E | Human | Esophagus | ESCC | 5.99e-06 | 2.06e-02 | 0.1236 |
124935 | SLC43A2 | P24T-E | Human | Esophagus | ESCC | 5.22e-09 | 2.06e-01 | 0.1287 |
124935 | SLC43A2 | P27T-E | Human | Esophagus | ESCC | 6.57e-14 | 1.32e-01 | 0.1055 |
124935 | SLC43A2 | P28T-E | Human | Esophagus | ESCC | 1.27e-08 | 9.73e-02 | 0.1149 |
124935 | SLC43A2 | P31T-E | Human | Esophagus | ESCC | 2.07e-07 | 1.62e-01 | 0.1251 |
124935 | SLC43A2 | P32T-E | Human | Esophagus | ESCC | 5.03e-11 | 2.54e-01 | 0.1666 |
124935 | SLC43A2 | P37T-E | Human | Esophagus | ESCC | 1.53e-11 | 1.95e-01 | 0.1371 |
124935 | SLC43A2 | P39T-E | Human | Esophagus | ESCC | 3.29e-02 | 2.70e-02 | 0.0894 |
124935 | SLC43A2 | P40T-E | Human | Esophagus | ESCC | 3.03e-02 | 9.91e-02 | 0.109 |
124935 | SLC43A2 | P42T-E | Human | Esophagus | ESCC | 1.45e-08 | 4.01e-01 | 0.1175 |
124935 | SLC43A2 | P47T-E | Human | Esophagus | ESCC | 3.91e-05 | 9.39e-02 | 0.1067 |
124935 | SLC43A2 | P48T-E | Human | Esophagus | ESCC | 8.43e-06 | 8.43e-02 | 0.0959 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510514 | Liver | Cirrhotic | negative regulation of transport | 141/4634 | 470/18723 | 5.06e-03 | 2.62e-02 | 141 |
GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC43A2 | SNV | Missense_Mutation | novel | c.1346N>T | p.Pro449Leu | p.P449L | Q8N370 | protein_coding | deleterious(0.03) | benign(0.444) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
SLC43A2 | SNV | Missense_Mutation | rs201054702 | c.235C>G | p.Leu79Val | p.L79V | Q8N370 | protein_coding | tolerated(0.57) | benign(0.015) | TCGA-A2-A25F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
SLC43A2 | SNV | Missense_Mutation | rs745538583 | c.1259N>A | p.Arg420Gln | p.R420Q | Q8N370 | protein_coding | deleterious(0.05) | possibly_damaging(0.593) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SLC43A2 | SNV | Missense_Mutation | rs779319098 | c.494N>T | p.Ser165Leu | p.S165L | Q8N370 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
SLC43A2 | SNV | Missense_Mutation | novel | c.1277N>A | p.Thr426Asn | p.T426N | Q8N370 | protein_coding | deleterious(0.01) | possibly_damaging(0.676) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD |
SLC43A2 | SNV | Missense_Mutation | rs201054702 | c.235C>G | p.Leu79Val | p.L79V | Q8N370 | protein_coding | tolerated(0.57) | benign(0.015) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC43A2 | insertion | Frame_Shift_Ins | novel | c.528_529insACCTTCGG | p.Ser177ThrfsTer9 | p.S177Tfs*9 | Q8N370 | protein_coding | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
SLC43A2 | SNV | Missense_Mutation | rs200135342 | c.380N>T | p.Ala127Val | p.A127V | Q8N370 | protein_coding | deleterious(0.03) | benign(0.092) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC43A2 | SNV | Missense_Mutation | c.1472T>A | p.Leu491Gln | p.L491Q | Q8N370 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC43A2 | SNV | Missense_Mutation | novel | c.655G>A | p.Gly219Arg | p.G219R | Q8N370 | protein_coding | deleterious(0.04) | possibly_damaging(0.799) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |